NuVasive treats first patient with NeoDisc

By Elaine Rigoli

Tampa, Fla., Sept. 18 - NuVasive, Inc. announced Monday the first-in-human U.S. use of its NeoDisc cervical disc replacement device.

The first procedure is part of a prospective, randomized, controlled, multi-center clinical trial to evaluate the safety and efficacy of NeoDisc by comparing the outcomes of patients to traditional anterior cervical discectomy and fusion.

This first implantation is ahead of the company's guidance to begin enrollment by the fourth quarter, according to a news release.

The San Diego medical device company said the clinical trial to evaluate NeoDisc includes a total patient population of about 500 across an estimated 20 clinical investigation sites.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.